Without prejudice
OPINION
Can Fenbendazole Cure Cancer?
According to a case series published in an oncology journal, the answer could be a resounding yes.
The case report highlights three cancer patients who were in pretty bad shape. But after taking fenbendazole, they all experienced a complete remission.
What Is Fenbendazole, and How Does it Work?
Fenbendazole (FBZ) is a medicine originally designed to treat worms and parasites in animals. Its sister drugs, Mebendazole and Albendazole, have had remarkable success treating similar ailments in humans with few side effects.
Recently, anecdotal reports have praised fenbendazole as a potentially miraculous anti-cancer drug. It works by destabilizing microtubules, the structures that help cancer cells divide and grow. By disrupting this process, fenbendazole effectively halts cancer cell division and slows or stops tumor growth.
Case Report, Clin Oncol Case Rep Vol: 4 Issue: 2
Fenbendazole Enhancing Anti-Tumor Effect (A Case Series) published by [Clinical Oncology] (Case Reports)
CASE 1
A 63-YEAR-OLD CAUCASIAN MALE
Presented with flank pain, rapid weight loss, and transient fever.
Abdominal Computed Topography (CT) revealed a 3 cm left solid renal mass.
Renal Cell Carcinoma (RCC)
Traditional drugs used then discontinued
One month after discontinuation, repeat MRI showed increase in size of recurrent left renal mass, pancreatic head and body lesion
He also started alternative therapy with FBZ 1 gm three times per week at the suggestion of one of his friends with head/neck cancer.
Interval MRI imaging found near complete resolution of the previously noted left renal mass, as well as decrease in pancreatic head/body and pelvic bone lesion.
Serial imaging for the past 10 months have not shown any evidence of recurrence or metastatic disease.
He has continued taking FBZ without any reported side effects.
CASE 2
A 72-YEAR-OLD CAUCASIAN MALE
· Urethral lesion
· Distal penectomy
· Pathology, showing; high-grade urothelial carcinoma of the urethra.
Four years later, the patient developed a cough, 5.5 cm × 4.0 cm left hilar mass and a left upper lobe nodule, with multiple abnormal lymph nodes
Bronchoscopy with biopsy revealed squamous carcinoma, (probable primary)
Chemotherapy given
Developed progressive retroperitoneal disease
The patient opted for complementary therapy with FBZ 1 gram orally three days per week,
· vitamin E 800 mg daily,
· curcumin 600 mg daily,
· and CBD oil
Serial CTs from the past 9 months showed progressive decrease in size to 0.5 cm × 0.5 cm, complete radiographic response.
CASE 3
A 63-YEAR-OLD CAUCASIAN FEMALE
CT imaging revealed a 7.5 cm right lateral bladder mass with extensions
Hydronephrosis, requiring; percutaneous nephrostomy.
Transurethral Resection of Bladder Tumor (TURBT) demonstrated a large necrotic mass, pathology confirming urothelial carcinoma with 85% squamous and 2% sarcomatoid histology.
6 cycles over the course of 4 months, along with concurrent FBZ 1 gram three times weekly.
Follow-up CT revealed no evidence of disease with minimal residual thickening in the right inferior bladder wall
She declined to proceed with cystectomy and remains on surveillance with no evidence of progression.
Discussion
We have three patients with different primary genitourinary tumors who demonstrated complete response after receiving FBZ therapy.
Given evidence of high tolerability and applicability to a wide range of malignancies, this warrants further investigation for FBZ and other benzimidazoles as safe chemotherapeutic options.
Conclusion
There remains limited data with few published studies on the anti-oncogenic properties of FBZ.
Other benzimidazoles have been studied to a larger extent, and the knowledge can be drawn upon to help guide future FBZ studies, and to gauge the efficacy of this drug class whether as a solitary agent or in combination therapy.
Given the potential benefits of FBZ with what seems to be a limited toxicity profile, further research is warranted to evaluate the clinical settings in which this medication may be beneficial and repurposed, for patients with progressive genitourinary malignancy and possibly in other malignant settings as well.
RELATED:
Journal Clinical Oncology (Case Reports) | HTMLVIEW HERE
Full peer reviewed PDF with radiology Original source: DOWNLOAD PDF
Acknowledgement Original Sources
Media Segment Credit to: Dr. John Campbell | YT-handle: @Campbellteaching | YT-tagline: (Fenbendazole) Fen ben for cancer [Full presentation] | YT-clip: 5Q5QjEPGNNg | YT-date-(AWST): 22 Nov 2024 | 4CM-notes:
Share this post